<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:mp ids='MP_0001845'>Inflammatory response</z:mp> plays a critical role in propagating tissue damage after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>CXCL12 is a key chemokine for leukocyte recruitment </plain></SENT>
<SENT sid="2" pm="."><plain>However, the role of CXCL12 and its receptor CXCR4 in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:mp ids='MP_0001845'>inflammatory response</z:mp> is unclear </plain></SENT>
<SENT sid="3" pm="."><plain>Here we use the pharmacological <z:chebi fb="68" ids="48706">antagonist</z:chebi> of CXCR4, AMD3100, to investigate the function of CXCL12/CXCR4 in regulating <z:mp ids='MP_0001845'>inflammatory response</z:mp> during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Adult male CD-1 mice (n=184) underwent permanent suture middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>AMD3100 was injected for 3 days (1 mg/kg/day) after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>Brain water content, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurological score, and myeloperoxidase (MPO) expression and activity were examined at 24, 48, and 72 hours after MCAO </plain></SENT>
<SENT sid="7" pm="."><plain>Proinflammatory cytokine <z:chebi fb="40" ids="33697">RNA</z:chebi> and protein levels in brain tissue were measured by RT-PCR and enzyme linked immunosorbent assay </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Neurological score was greatly improved in AMD3100-treated mice compared with the control mice 3 days after MCAO (P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0002181'>Brain edema</z:hpo>-induced change of water content, IgG protein leakage, Evans blue extravasation, occludin, and ZO-1 expression in ipsilateral hemisphere were alleviated by <z:hpo ids='HP_0011009'>acute</z:hpo> treatment of AMD3100 </plain></SENT>
<SENT sid="10" pm="."><plain>MPO expression and activity revealed that AMD3100 profoundly reduced the number of MPO-positive cells in the ischemic region (P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>It also attenuated proinflammatory cytokines including interleukin 6, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor α, and interferon γ; their <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels changed accordingly compared with the controls (P&lt;0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: CXCR4 <z:chebi fb="68" ids="48706">antagonist</z:chebi> AMD3100 significantly suppressed <z:mp ids='MP_0001845'>inflammatory response</z:mp> and reduced blood-brain barrier disruption after MCAO </plain></SENT>
<SENT sid="13" pm="."><plain>AMD3100 attenuated <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> by suppressing leukocyte migration and infiltration, in addition to reducing proinflammatory cytokine expression in the ischemic region </plain></SENT>
</text></document>